Eric P. Lefkofsky Sells 84,640 Shares of Tempus AI, Inc. (NASDAQ:TEM) Stock

Tempus AI, Inc. (NASDAQ:TEM) CEO Eric P. Lefkofsky sold 84,640 shares of the business’s stock in a transaction on Wednesday, February 19th. The shares were sold at an average price of $80.87, for a total transaction of $6,844,836.80. Following the sale, the chief executive officer now owns 4,964,820 shares of the company’s stock, valued at approximately $401,504,993.40. The trade was a 1.68 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Tempus AI Stock Performance

TEM stock opened at $68.09 on Friday. The company has a 50-day simple moving average of $50.29 and a 200 day simple moving average of $51.72. Tempus AI, Inc. has a fifty-two week low of $22.89 and a fifty-two week high of $91.45. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17.

Institutional Investors Weigh In On Tempus AI

Institutional investors have recently bought and sold shares of the stock. Operose Advisors LLC acquired a new stake in Tempus AI in the fourth quarter worth about $25,000. First Horizon Advisors Inc. acquired a new stake in Tempus AI in the third quarter worth about $30,000. Farther Finance Advisors LLC acquired a new stake in Tempus AI in the fourth quarter worth about $34,000. Prestige Wealth Management Group LLC lifted its holdings in Tempus AI by 910.4% in the fourth quarter. Prestige Wealth Management Group LLC now owns 1,071 shares of the company’s stock worth $36,000 after purchasing an additional 965 shares during the period. Finally, NewEdge Advisors LLC acquired a new stake in Tempus AI in the fourth quarter worth about $49,000. Institutional investors and hedge funds own 24.22% of the company’s stock.

Analyst Upgrades and Downgrades

TEM has been the subject of several recent research reports. Guggenheim initiated coverage on shares of Tempus AI in a research note on Monday, December 9th. They set a “buy” rating and a $74.00 target price for the company. Piper Sandler reiterated a “neutral” rating and set a $70.00 target price (up previously from $40.00) on shares of Tempus AI in a research note on Tuesday, November 12th. Wolfe Research began coverage on shares of Tempus AI in a research note on Friday, December 13th. They set an “outperform” rating and a $60.00 target price for the company. Needham & Company LLC reissued a “buy” rating and set a $56.00 price target on shares of Tempus AI in a report on Tuesday, January 14th. Finally, William Blair downgraded shares of Tempus AI from an “outperform” rating to a “market perform” rating in a report on Wednesday, February 12th. Four research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $58.55.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.